Trial · NCT06148792
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The incidence risk of vivax parasitaemia | 4 months | The incidence risk (time to first event) of any P. vivax parasitaemia during the 4-month follow up period as determined by microscopy. * compared between TQRevised and the PQ7 (non-inferiority) * compared between TQRevised and TQStandard (superiority) |
| Secondary | The incidence risk of vivax parasitaemia | 4 months | The incidence risk (time to first event) of any P. vivax parasitaemia during the 4-month follow up period as determined by microscopy compared between TQStandard and PQ7 |
| Secondary | The incidence risk of symptomatic vivax parasitaemia | 4 months | The incidence risk (time to first event) of symptomatic P. vivax parasitaemia during the 4 months follow up period as determined by microscopy |
| Secondary | The incidence risk of vivax parasitaemia | 6 months | The incidence risk (time to first event) of any P. vivax parasitaemia at 6-month follow up as determined by microscopy |
| Secondary | The incidence risk of symptomatic vivax parasitaemia | 6 months | The incidence risk (time to first event) of symptomatic P. vivax parasitaemia at 6-month follow up as determined by microscopy |
| Secondary | The incidence rate of vivax parasitaemia | 6 months | The incidence rate (events per person-time) of any P. vivax parasitaemia during the 6 months follow up period as determined by microscopy |
| Secondary | The incidence rate of symptomatic vivax parasitaemia | 6 months | The incidence rate (events per person-time) of symptomatic P. vivax parasitaemia during the 6 months follow up period as determined by microscopy |
| Secondary | The incidence risk of anaemia | 7 and 14 days, 6 months | The incidence risk of developing severe anaemia (Hb \< 5g/dl) or moderate (5g/dl and \<7g/dl) anaemia within 7 and 14 days of starting treatment and/or requiring blood transfusion within the 6 months follow up period |
| Secondary | The incidence risk of an acute drop in Hb | 7 and 14 days | The incidence risk of an acute drop in Hb of \>25% to \<7g/dl within 7 and 14 days of starting treatment |
| Secondary | Adverse events | 42 days | The number and proportion of adverse and serious adverse events in each arm within 42 days after start of treatment |
| Secondary | Meth Hb concentration | day 7 | day 7 methaemoglobin concentration |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06148792/registered